said a federal court awarded
$16.2 million in damages plus pre-judgment interest in a patent dispute.
Stratagene, La Jolla, Calif., said it intends to appeal the order handed down by the U.S. District Court for the Western District of Texas.
The court held that Invitrogen's 4,981,797 patent is valid and that Stratagene infringed that patent by making and selling its competent E. coli cell products.
Stratagene shares fell 60 cents to $6.23.
This story was created through a joint venture between TheStreet.com and IRIS.